Loading
institutionsInstitution
Osaka University Graduate School of Medicine / Osaka University Hospital
Japanese national university whose medical school led CheckMate 648 in oesophageal cancer and whose Immunology Frontier Research Center is home to Shimon Sakaguchi, discoverer of regulatory T cells.
Also called: Osaka University大阪大学Immunology Frontier Research Center (IFReC)WPI-IFReC
Overview
Osaka University is one of Japan's leading research universities; its Graduate School of Medicine and University Hospital are on the Suita campus north of Osaka. The Department of Gastroenterological Surgery, under Yuichiro Doki, led CheckMate 648, the 2022 trial that established nivolumab-based first-line treatment for advanced oesophageal squamous-cell carcinoma. The Immunology Frontier Research Center (IFReC) hosts Shimon Sakaguchi, who discovered regulatory T cells and the role of FOXP3, work that underlies much of cancer immunotherapy. The Osaka International Cancer Institute is a separate prefectural cancer centre in the city.
Location
Suita, Osaka, JP
Type
university
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#540 · 6 points (0 Newsweek + 0 NCI + 6 from 3 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to The University of Osaka, including child institutions. 950 works · 8,406 citations · 74% open access · 8% clinical trials · 2% reviews.
Oncology works per year
1922022
2032023
2162024
1982025
1412026
Most works
- Hidetoshi Eguchi140 works
- Yuichiro Doki104 works
- Shogo Kobayashi51 works
- Mamoru Uemura50 works
- Daisaku Yamada47 works
- Taroh Satoh47 works
- Norikatsu Miyoshi46 works
- Hidenori Takahashi46 works
- Takayuki Ogino46 works
- Takehiro Noda41 works
Most cited
- Gastroenterological surgery
- Immunology (IFReC)
- Oesophageal cancer trials
Shimon Sakaguchi
Distinguished Professor, Immunology Frontier Research Center, Osaka University
Regulatory T cellsImmune toleranceAutoimmunity
Discovered regulatory T cells, the immune cells that suppress anti-tumour responses and are now a target for cancer therapy.
Yuichiro Doki
Gastrointestinal surgeon, Osaka University
Oesophageal squamous-cell carcinomaGastrointestinal surgeryImmunotherapy trials
Japanese surgeon who was lead author of CheckMate 648, which established nivolumab-based first-line treatment for advanced oesophageal squamous-cell carcinoma.
Similar pages
- Key paperCheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma
- TrialQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
- TrialSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
- TargetTEC
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
- TrialA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
- TargetCLIP1
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
- TrialStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.